His primary areas of study are Internal medicine, Surgery, Oncology, Melanoma and Immunology. Svetomir N. Markovic works mostly in the field of Internal medicine, limiting it down to concerns involving Gastroenterology and, occasionally, Hazard ratio and Survival rate. His Oncology research includes elements of Meta-analysis, Survival analysis, Disease and Monoclonal.
His study in Melanoma is interdisciplinary in nature, drawing from both Differential diagnosis, Ipilimumab and Adjuvant therapy. His Immunology research is multidisciplinary, relying on both Cancer and Metastasis. Svetomir N. Markovic has researched Lymphocyte in several fields, including Stem cell and Lymphoma.
Internal medicine, Oncology, Melanoma, Immunology and Surgery are his primary areas of study. His Internal medicine research integrates issues from Gastroenterology and Pathology. His work carried out in the field of Gastroenterology brings together such families of science as Hematopoietic stem cell transplantation, Area under the curve, Neutropenia and Hazard ratio, Confidence interval.
His Oncology study integrates concerns from other disciplines, such as Pembrolizumab, Metastatic melanoma, Clinical trial and Ipilimumab. His studies deal with areas such as Metastasis, Disease and Immunotherapy as well as Melanoma. The concepts of his Immunology study are interwoven with issues in Cancer and Cytotoxic T cell.
The scientist’s investigation covers issues in Internal medicine, Melanoma, Cancer research, Cancer and Oncology. Many of his studies involve connections with topics such as Gastroenterology and Internal medicine. The various areas that Svetomir N. Markovic examines in his Melanoma study include Immunohistochemistry, Lesion, Metastasis and Disease.
His research in Cancer research intersects with topics in Bevacizumab and Immune checkpoint. The study incorporates disciplines such as Interquartile range, Antibody, Albumin and In vivo in addition to Cancer. His study on Oncology also encompasses disciplines like
Svetomir N. Markovic focuses on Internal medicine, Melanoma, Immunotherapy, Oncology and Cancer research. His study in Adverse effect, Cohort, Meta-analysis, Pembrolizumab and Resiquimod is carried out as part of his studies in Internal medicine. His Melanoma research is multidisciplinary, incorporating elements of Chemokine, Immune system and Clinical trial, Phases of clinical research.
The Immunotherapy study combines topics in areas such as Lung cancer, Chemotherapy and Immunogenicity. Svetomir N. Markovic focuses mostly in the field of Oncology, narrowing it down to topics relating to Hazard ratio and, in certain cases, Randomized controlled trial. He has researched Cancer research in several fields, including Immune checkpoint, Cytotoxic T cell, CD40, T cell and Tumor necrosis factor receptor.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials
Edward L. Korn;Ping Yu Liu;Sandra J. Lee;Judith Anne W. Chapman.
Journal of Clinical Oncology (2008)
Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis
Svetomir N. Markovic;Lori A. Erickson;Ravi D. Rao;Robert R. McWilliams.
Mayo Clinic Proceedings (2007)
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.
Yucai Wang;Shouhao Zhou;Shouhao Zhou;Fang Yang;Xinyue Qi.
JAMA Oncology (2019)
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma.
Luis F. Porrata;Morie A. Gertz;David J. Inwards;Mark R. Litzow.
Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents.
Shernan G. Holtan;Douglas J. Creedon;Paul Haluska;Svetomir N. Markovic.
Mayo Clinic Proceedings (2009)
Therapy for metastatic melanoma: the past, present, and future
Laura Finn;Svetomir N Markovic;Richard W Joseph.
BMC Medicine (2012)
B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders.
Ryan A. Wilcox;Andrew L. Feldman;David A. Wada;Zhi Zhang Yang.
Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma.
Stephen M. Ansell;Thomas E. Witzig;Paul J. Kurtin;Jeff A. Sloan.
Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies.
Justin C. Kao;Bing Liao;Svetomir Nenad Markovic;Christopher Jon Klein.
JAMA Neurology (2017)
Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin’s lymphoma
Luis F. Porrata;Kay Ristow;Joseph P. Colgan;Thomas M. Habermann.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: